ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal
ADAR1's Stake in Keros: ADAR1 Capital Management, the largest stockholder of Keros Therapeutics with 13.3% ownership, expressed disappointment over the Board's refusal to engage on strategic matters.
Request for Engagement: ADAR1 previously requested a meeting to discuss maximizing shareholder value but was met with reluctance from Keros' management, who referred them to a financial advisor instead.
Concerns Over Capital Return: The firm is concerned about the lack of updates regarding Keros' plan to return $375 million in excess capital to shareholders and urges the Board to communicate a clear plan.
Potential Board Changes: If the Board continues to refuse engagement, ADAR1 plans to seek new directors at the next Annual Meeting who will be more receptive to shareholder input and collaboration.
Trade with 70% Backtested Accuracy
Analyst Views on KROS
About KROS
About the author
Five Low Price-to-Book Stocks to Buy: AES, BorgWarner, Enersys, PG&E, Keros
- Low P/B Stocks: The AES Corporation, BorgWarner, Enersys, PG&E, and Keros Therapeutics are highlighted as low price-to-book stocks to buy as 2025 approaches, indicating strong value recognition among investors.
- Growth Potential: AES has a projected 3-5 year EPS growth rate of 11.2%, while Keros Therapeutics boasts an impressive 36.5%, showcasing robust growth prospects in their respective sectors.
- Industry Rankings: Both AES and PG&E hold a Zacks Rank of #2, reflecting their strong market positions and attracting interest from value investors.
- Investment Strategy: By focusing on stocks with a P/B ratio below 1, investors can identify undervalued companies, thereby uncovering potential investment opportunities amidst market fluctuations.
Zacks.com Spotlights StoneCo, General Motors, Enersys, Deutsche, and Keros
Value Stocks Overview: The article discusses various stocks including StoneCo, General Motors, Enersys, Deutsche Bank, and Keros Therapeutics, highlighting the importance of the price-to-book (P/B) ratio as a valuation tool for identifying undervalued stocks with growth potential.
Understanding Book Value: Book value is defined as the total value remaining for shareholders if a company were to liquidate, calculated by subtracting total liabilities from total assets, and is crucial for assessing whether a stock is under- or overpriced.
P/B Ratio Insights: A P/B ratio of less than one indicates a potentially undervalued stock, while a ratio above one suggests overvaluation; however, investors should be cautious as a low P/B can also signal poor asset returns or overstated assets.
Investment Recommendations: The article provides insights into the projected earnings growth rates for the mentioned companies, encouraging readers to consider these stocks for investment while also recommending the use of additional financial ratios for informed decision-making.
Reasons to Consider Keros Therapeutics, Inc. (KROS) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise, making it a popular yet complex strategy among investors.
Keros Therapeutics Performance: Keros Therapeutics, Inc. (KROS) has a Momentum Style Score of B and a Zacks Rank of #1 (Strong Buy), with significant price increases over various time frames, outperforming both its industry and the S&P 500.
Earnings Estimate Revisions: KROS has seen a positive trend in earnings estimate revisions, with 7 estimates moving higher recently, boosting its consensus estimate significantly, indicating strong future potential.
Investment Recommendation: Given its strong performance metrics and positive momentum indicators, Keros Therapeutics is recommended as a promising stock pick for investors looking for short-term gains.
B of A Securities Keeps Neutral Rating on Keros Therapeutics (KROS)
Analyst Recommendation: B of A Securities has maintained a Neutral recommendation for Keros Therapeutics (NasdaqGM:KROS) as of November 28, 2025, with an average one-year price target of $23.72/share, indicating a potential upside of 35.59% from its current price of $17.49/share.
Financial Projections: Keros Therapeutics is projected to have an annual revenue of $22 million, reflecting a significant decrease of 91.07%, with a non-GAAP EPS forecast of -4.50.
Fund Sentiment: There are currently 312 funds reporting positions in Keros Therapeutics, with a slight increase in ownership and a bullish outlook indicated by a put/call ratio of 0.82.
Shareholder Activity: Notable shareholders include ADAR1 Capital Management, Madison Avenue Partners, and Western Standard, with varying changes in their shareholdings over the last quarter, reflecting mixed portfolio adjustments.
B of A Securities Keeps Neutral Rating on Keros Therapeutics and Increases Price Target to $19
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.
Keros Therapeutics Reveals Initial Findings from Tender Offer
Tender Offer Announcement: Keros Therapeutics announced the preliminary results of its cash tender offer to repurchase up to 10,950,165 shares of its common stock at a price of $17.75 per share, totaling approximately $194.4 million, which expired on November 18, 2025.
Shares Tendered: Approximately 16,659,732 shares were validly tendered, exceeding the number Keros intended to repurchase, leading to a pro rata acceptance of shares.
Company Overview: Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to TGF-ß protein signaling, with key products targeting neuromuscular diseases and cytopenias.
Forward-Looking Statements: The announcement includes forward-looking statements regarding the tender offer and potential risks, emphasizing that actual results may differ from expectations due to various uncertainties.
Five Low Price-to-Book Stocks to Buy: AES, BorgWarner, Enersys, PG&E, Keros
- Low P/B Stocks: The AES Corporation, BorgWarner, Enersys, PG&E, and Keros Therapeutics are highlighted as low price-to-book stocks to buy as 2025 approaches, indicating strong value recognition among investors.
- Growth Potential: AES has a projected 3-5 year EPS growth rate of 11.2%, while Keros Therapeutics boasts an impressive 36.5%, showcasing robust growth prospects in their respective sectors.
- Industry Rankings: Both AES and PG&E hold a Zacks Rank of #2, reflecting their strong market positions and attracting interest from value investors.
- Investment Strategy: By focusing on stocks with a P/B ratio below 1, investors can identify undervalued companies, thereby uncovering potential investment opportunities amidst market fluctuations.
Zacks.com Spotlights StoneCo, General Motors, Enersys, Deutsche, and Keros
Value Stocks Overview: The article discusses various stocks including StoneCo, General Motors, Enersys, Deutsche Bank, and Keros Therapeutics, highlighting the importance of the price-to-book (P/B) ratio as a valuation tool for identifying undervalued stocks with growth potential.
Understanding Book Value: Book value is defined as the total value remaining for shareholders if a company were to liquidate, calculated by subtracting total liabilities from total assets, and is crucial for assessing whether a stock is under- or overpriced.
P/B Ratio Insights: A P/B ratio of less than one indicates a potentially undervalued stock, while a ratio above one suggests overvaluation; however, investors should be cautious as a low P/B can also signal poor asset returns or overstated assets.
Investment Recommendations: The article provides insights into the projected earnings growth rates for the mentioned companies, encouraging readers to consider these stocks for investment while also recommending the use of additional financial ratios for informed decision-making.
Reasons to Consider Keros Therapeutics, Inc. (KROS) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise, making it a popular yet complex strategy among investors.
Keros Therapeutics Performance: Keros Therapeutics, Inc. (KROS) has a Momentum Style Score of B and a Zacks Rank of #1 (Strong Buy), with significant price increases over various time frames, outperforming both its industry and the S&P 500.
Earnings Estimate Revisions: KROS has seen a positive trend in earnings estimate revisions, with 7 estimates moving higher recently, boosting its consensus estimate significantly, indicating strong future potential.
Investment Recommendation: Given its strong performance metrics and positive momentum indicators, Keros Therapeutics is recommended as a promising stock pick for investors looking for short-term gains.
B of A Securities Keeps Neutral Rating on Keros Therapeutics (KROS)
Analyst Recommendation: B of A Securities has maintained a Neutral recommendation for Keros Therapeutics (NasdaqGM:KROS) as of November 28, 2025, with an average one-year price target of $23.72/share, indicating a potential upside of 35.59% from its current price of $17.49/share.
Financial Projections: Keros Therapeutics is projected to have an annual revenue of $22 million, reflecting a significant decrease of 91.07%, with a non-GAAP EPS forecast of -4.50.
Fund Sentiment: There are currently 312 funds reporting positions in Keros Therapeutics, with a slight increase in ownership and a bullish outlook indicated by a put/call ratio of 0.82.
Shareholder Activity: Notable shareholders include ADAR1 Capital Management, Madison Avenue Partners, and Western Standard, with varying changes in their shareholdings over the last quarter, reflecting mixed portfolio adjustments.
B of A Securities Keeps Neutral Rating on Keros Therapeutics and Increases Price Target to $19
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.
Keros Therapeutics Reveals Initial Findings from Tender Offer
Tender Offer Announcement: Keros Therapeutics announced the preliminary results of its cash tender offer to repurchase up to 10,950,165 shares of its common stock at a price of $17.75 per share, totaling approximately $194.4 million, which expired on November 18, 2025.
Shares Tendered: Approximately 16,659,732 shares were validly tendered, exceeding the number Keros intended to repurchase, leading to a pro rata acceptance of shares.
Company Overview: Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to TGF-ß protein signaling, with key products targeting neuromuscular diseases and cytopenias.
Forward-Looking Statements: The announcement includes forward-looking statements regarding the tender offer and potential risks, emphasizing that actual results may differ from expectations due to various uncertainties.
